Compare SKLZ & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKLZ | LUNG |
|---|---|---|
| Founded | 2012 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.0M | 63.6M |
| IPO Year | N/A | 2020 |
| Metric | SKLZ | LUNG |
|---|---|---|
| Price | $4.72 | $2.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $14.00 | $6.81 |
| AVG Volume (30 Days) | 64.5K | ★ 986.2K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $92,256,000.00 | $91,664,000.00 |
| Revenue This Year | $13.33 | $9.21 |
| Revenue Next Year | $12.68 | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 15.59 |
| 52 Week Low | $3.54 | $1.31 |
| 52 Week High | $9.11 | $9.37 |
| Indicator | SKLZ | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 29.06 | 52.16 |
| Support Level | $5.01 | $2.16 |
| Resistance Level | $5.98 | $2.65 |
| Average True Range (ATR) | 0.25 | 0.19 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 3.01 | 36.43 |
Skillz Inc is a two-sided mobile gaming platform that connects developers with competitive players. The company's reportable business segments are: the Skillz segment and the Aarki segment. Skillz segment's highlights include Monetize Through Competitions, Player Matching, Cross-Platform Support, Comprehensive Analytics, and Focus on Game Development. Aarki is an artificial intelligence company that delivers advertising solutions. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube among others. The majority of its revenue is generated from the Skillz segment. Geographically, the company derives its key revenue from the United States and the rest from Israel, China, Malta, and other countries.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.